Eloxx Pharmaceuticals, Inc. Common Stock (ELOX)
NASDAQ
13.22
+0.72 (+5.76%)
Closed
Oct 20, 2026
Day's Range
12.8613.77
52 wk Range
0.0011023.40
Financial Statements - ELOX - Eloxx Pharmaceuticals, Inc. Common Stock
Revenue
0▼ 100.0%
Net Income
-5.99M▼ 90.7%
EBITDA
-6.27M▼ 182.3%
Free Cash Flow
-6.32M▼ 34.2%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 6.35M | 0 | 0 | 0 | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -6.43M | -2.46M | -17.28M | -34.41M | -66.01M | -29.43M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 1.30M | 442K | 1.13M | 29K | 542K | -4.06M |
| Pre Tax Income | -5.99M | -3.14M | -17.05M | -36.06M | -66.72M | -34.57M |
| Income Tax | - | - | - | - | - | 0 |
| Net Income | -5.99M | -3.14M | -17.05M | -36.06M | -66.72M | -34.57M |
| EPS Basic | -5.39 | -9.24 | -6.63 | -16.65 | -38 | -34.4 |
| EPS Diluted | -5.39 | -9.24 | -6.63 | -16.65 | -38 | -34.4 |
| Basic Shares Outstanding | 1.12M | 341.70K | 2.57M | 2.16M | 1.74M | 1M |
| Diluted Shares Outstanding | 1.12M | 341.70K | 2.57M | 2.16M | 1.74M | 1M |
| Ebit | -4.94M | -1.99M | -15.90M | -34.11M | -65.46M | -33.16M |
| Ebitda | -6.27M | -2.22M | -16.48M | -33.37M | -65.05M | -28.52M |
| Net Income Continuous Operations | -5.99M | -3.14M | -17.05M | -36.06M | -66.72M | -34.57M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
